Pronutria Biosciences pulls in $39 mln Series C

Cambridge, Massachusetts-based Pronutria Biosiences, a developer of treatments to mediate amino acid biology, has closed $39 million in Series C funding. Fidelity Management & Research Company led the round with participation from other investors that included Flagship Ventures.

205 Views

Denali launches with $217 mln

Denali Therapeutics Inc, a developer of treatments for neurodegenerative diseases, has launched with a $217 million investment commitment. The investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund.

126 Views

Joule grabs $40 mln

Bedford, Massachusetts-based alternative fuel developer Joule has raised $40 million in funding. The investors included Flagship Ventures.

VC-backed Blend Therapeutics appoints Fromkin as president and CEO

Watertown, Massachusetts-based Blend Therapeutics Inc, a biopharmaceutical company focused on treating patients with solid tumor cancers, has named Drew Fromkin as president, CEO and a member of the company’s board of directors. Previously, Fromkin worked at Clinical Data Inc where he served as President and CEO. Blend Therapeutics’ backers include Eminent Venture Capital, Flagship Ventures, NanoDimension and New Enterprise Associates.

MPM Capital adds new MD to team

MPM Capital named Gregory Sieczkiewicz as managing director and chief counsel, intellectual property. The appointment is effective immediately. Previously, Sieczkiewicz worked at Flagship Ventures where he served as vice president of intellectual property.

Flagship Ventures to back Red Rock Biofuels

Flagship Ventures has agreed to invest in Red Rock BioFuels LLC. No financial terms were disclosed. Also, Flagship Ventures will take a seat on Red Rock’s board of directors. Based in Fort Collins, Colorado, Red Rock Biofuels is a provider of renewable biofuels.

131 Views

Blend Therapeutics scores $21 mln

Watertown, Mass.-based Blend Therapeutics, a biopharmaceutical firm focused on treating cancer, has raised $21 million in funding. Blend’s investors include New Enterprise Associates, Flagship Ventures, NanoDimension and Eminent Venture Capital.

VC-backed Acceleron Pharma adds to board of directors

Acceleron Pharma has appointed Dr. Francois Nader to its board of directors. Nader is president, CEO and a member of the board of directors of NPS Pharma. Acceleron Pharma’s backers include Advanced Technology Ventures, Flagship Ventures, OrbiMed Advisors, Polaris Ventures and Venrock. Based in Cambridge, Mass., Acceleron is focused on developing novel protein therapeutics for cancer and rare diseases.

Seres Health fetches $48 mln

Seres Health has raised $48 million in Series C funding. The investors in this round were not named; however, the firm was seeded by Flagship Ventures. Based in Cambridge, Mass., Seres Health is a biotherapeutic company focused on developing drugs that target the human microbiome.

227 Views

Flagship Ventures backs Symbiota

Symbiota has closed $7.5 million in Series A funding from Flagship Ventures. Based in Cambridge, Mass., Symbiota is a provider of microbial solutions.

138 Views

Selecta Biosciences raises $20 million

Selecta Biosciences said Wednesday it has secured $20 million in equity funding from new and all of Selecta’s existing investors. Including the $20 million, Selecta said it has obtained a total of $78.6 Million in funding to date. Investors include Polaris Venture Partners, Flagship Ventures, OrbiMed Advisors, NanoDimension, Rusnano, I2BF, Eminent Venture Capital and Leukon Investments. Selecta is a clinical stage biotechnology company that is developing a class of targeted antigen-specific immune therapies.

153 Views

Visterra closes $30 mln Series B

Biotechnology company Visterra has completed a $30 million Series B financing round. The round was co-led by new Visterra investors Merck Research Labs Venture Fund, Vertex Venture Holdings and Temasek. Existing investors Polaris Partners, Flagship Ventures, Omega Funds and Alexandria Venture Investments and a new investor Cycad Group also participated.

PE HUB Community

Join the 12519 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget